ENOVIS CORP (ENOV) Stock Fundamental Analysis
USA - NYSE:ENOV - US1940141062 - Common Stock
29.99 USD
-0.88 (-2.85%)
29.99 USD
0 (0%)
Taking everything into account, ENOV scores 4 out of 10 in our fundamental rating. ENOV was compared to 189 industry peers in the Health Care Equipment & Supplies industry. While ENOV is still in line with the averages on profitability rating, there are concerns on its financial health. ENOV may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
ENOV had positive earnings in the past year.
In the past year ENOV had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: ENOV reported negative net income in multiple years.
ENOV had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
ENOV has a Return On Assets (-30.84%) which is comparable to the rest of the industry.
ENOV has a Return On Equity (-67.66%) which is in line with its industry peers.
ENOV has a Return On Invested Capital of 0.12%. This is in the better half of the industry: ENOV outperforms 65.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.84% | ||
| ROE | -67.66% | ||
| ROIC | 0.12% |
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ENOV's Operating Margin of 0.25% is fine compared to the rest of the industry. ENOV outperforms 65.61% of its industry peers.
In the last couple of years the Operating Margin of ENOV has declined.
ENOV has a Gross Margin of 57.19%. This is comparable to the rest of the industry: ENOV outperforms 55.56% of its industry peers.
In the last couple of years the Gross Margin of ENOV has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.25% | ||
| PM (TTM) | N/A | ||
| GM | 57.19% |
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ENOV is destroying value.
The number of shares outstanding for ENOV has been increased compared to 1 year ago.
The number of shares outstanding for ENOV has been increased compared to 5 years ago.
Compared to 1 year ago, ENOV has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 0.83, we must say that ENOV is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ENOV (0.83) is comparable to the rest of the industry.
The Debt to FCF ratio of ENOV is 59.72, which is on the high side as it means it would take ENOV, 59.72 years of fcf income to pay off all of its debts.
ENOV has a Debt to FCF ratio of 59.72. This is in the better half of the industry: ENOV outperforms 66.67% of its industry peers.
A Debt/Equity ratio of 0.66 indicates that ENOV is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.66, ENOV is doing worse than 66.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 59.72 | ||
| Altman-Z | 0.83 |
ROIC/WACC0.02
WACC7.33%
2.3 Liquidity
A Current Ratio of 2.22 indicates that ENOV has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.22, ENOV is in line with its industry, outperforming 41.27% of the companies in the same industry.
ENOV has a Quick Ratio of 1.16. This is a normal value and indicates that ENOV is financially healthy and should not expect problems in meeting its short term obligations.
ENOV's Quick ratio of 1.16 is on the low side compared to the rest of the industry. ENOV is outperformed by 70.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.22 | ||
| Quick Ratio | 1.16 |
3. Growth
3.1 Past
ENOV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.14%, which is quite impressive.
ENOV shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -16.18% yearly.
The Revenue has grown by 11.57% in the past year. This is quite good.
ENOV shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -8.73% yearly.
EPS 1Y (TTM)26.14%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%2.74%
Revenue 1Y (TTM)11.57%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%8.65%
3.2 Future
The Earnings Per Share is expected to grow by 23.19% on average over the next years. This is a very strong growth
Based on estimates for the next years, ENOV will show a quite strong growth in Revenue. The Revenue will grow by 8.87% on average per year.
EPS Next Y12.58%
EPS Next 2Y12.38%
EPS Next 3Y13.12%
EPS Next 5Y23.19%
Revenue Next Year7.28%
Revenue Next 2Y6.83%
Revenue Next 3Y6.79%
Revenue Next 5Y8.87%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 9.01, which indicates a very decent valuation of ENOV.
Based on the Price/Earnings ratio, ENOV is valued cheaper than 93.12% of the companies in the same industry.
When comparing the Price/Earnings ratio of ENOV to the average of the S&P500 Index (25.89), we can say ENOV is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 8.39, the valuation of ENOV can be described as reasonable.
Based on the Price/Forward Earnings ratio, ENOV is valued cheaply inside the industry as 95.24% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of ENOV to the average of the S&P500 Index (34.59), we can say ENOV is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.01 | ||
| Fwd PE | 8.39 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ENOV indicates a rather cheap valuation: ENOV is cheaper than 89.42% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ENOV indicates a somewhat cheap valuation: ENOV is cheaper than 70.37% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 75.3 | ||
| EV/EBITDA | 10.22 |
4.3 Compensation for Growth
ENOV's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ENOV's earnings are expected to grow with 13.12% in the coming years.
PEG (NY)0.72
PEG (5Y)N/A
EPS Next 2Y12.38%
EPS Next 3Y13.12%
5. Dividend
5.1 Amount
ENOV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
29.99
-0.88 (-2.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners121.31%
Inst Owner Change0.1%
Ins Owners1.19%
Ins Owner Change7.81%
Market Cap1.71B
Revenue(TTM)2.23B
Net Income(TTM)-1.37B
Analysts83.75
Price Target52.79 (76.03%)
Short Float %12.75%
Short Ratio8.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.55%
Min EPS beat(2)7.76%
Max EPS beat(2)13.35%
EPS beat(4)4
Avg EPS beat(4)8.22%
Min EPS beat(4)4.97%
Max EPS beat(4)13.35%
EPS beat(8)8
Avg EPS beat(8)7.21%
EPS beat(12)12
Avg EPS beat(12)8.15%
EPS beat(16)16
Avg EPS beat(16)8.66%
Revenue beat(2)0
Avg Revenue beat(2)-0.15%
Min Revenue beat(2)-0.21%
Max Revenue beat(2)-0.09%
Revenue beat(4)0
Avg Revenue beat(4)-0.8%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)-0.09%
Revenue beat(8)2
Avg Revenue beat(8)-0.81%
Revenue beat(12)4
Avg Revenue beat(12)-0.8%
Revenue beat(16)5
Avg Revenue beat(16)-4.71%
PT rev (1m)-4.75%
PT rev (3m)-11.45%
EPS NQ rev (1m)-4.99%
EPS NQ rev (3m)-5.2%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)2.89%
Revenue NQ rev (1m)-1.02%
Revenue NQ rev (3m)-1.15%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.83%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.01 | ||
| Fwd PE | 8.39 | ||
| P/S | 0.77 | ||
| P/FCF | 75.3 | ||
| P/OCF | 7.9 | ||
| P/B | 0.85 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.22 |
EPS(TTM)3.33
EY11.1%
EPS(NY)3.57
Fwd EY11.92%
FCF(TTM)0.4
FCFY1.33%
OCF(TTM)3.8
OCFY12.66%
SpS39.07
BVpS35.35
TBVpS-8.37
PEG (NY)0.72
PEG (5Y)N/A
Graham Number51.47
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.84% | ||
| ROE | -67.66% | ||
| ROCE | 0.15% | ||
| ROIC | 0.12% | ||
| ROICexc | 0.12% | ||
| ROICexgc | 0.34% | ||
| OM | 0.25% | ||
| PM (TTM) | N/A | ||
| GM | 57.19% | ||
| FCFM | 1.02% |
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-45.54%
ROICexc growth 3YN/A
ROICexc growth 5Y-43.8%
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
F-Score4
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 59.72 | ||
| Debt/EBITDA | 4.5 | ||
| Cap/Depr | 66.6% | ||
| Cap/Sales | 8.7% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 72.98% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.22 | ||
| Quick Ratio | 1.16 | ||
| Altman-Z | 0.83 |
F-Score4
WACC7.33%
ROIC/WACC0.02
Cap/Depr(3y)55.91%
Cap/Depr(5y)50.8%
Cap/Sales(3y)7.49%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.14%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%2.74%
EPS Next Y12.58%
EPS Next 2Y12.38%
EPS Next 3Y13.12%
EPS Next 5Y23.19%
Revenue 1Y (TTM)11.57%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%8.65%
Revenue Next Year7.28%
Revenue Next 2Y6.83%
Revenue Next 3Y6.79%
Revenue Next 5Y8.87%
EBIT growth 1Y-35.24%
EBIT growth 3YN/A
EBIT growth 5Y-48.51%
EBIT Next Year74.87%
EBIT Next 3Y29.81%
EBIT Next 5Y28.11%
FCF growth 1Y122.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y609.06%
OCF growth 3Y-31.69%
OCF growth 5Y-2.82%
ENOVIS CORP / ENOV FAQ
What is the ChartMill fundamental rating of ENOVIS CORP (ENOV) stock?
ChartMill assigns a fundamental rating of 4 / 10 to ENOV.
Can you provide the valuation status for ENOVIS CORP?
ChartMill assigns a valuation rating of 8 / 10 to ENOVIS CORP (ENOV). This can be considered as Undervalued.
Can you provide the profitability details for ENOVIS CORP?
ENOVIS CORP (ENOV) has a profitability rating of 4 / 10.
What is the earnings growth outlook for ENOVIS CORP?
The Earnings per Share (EPS) of ENOVIS CORP (ENOV) is expected to grow by 12.58% in the next year.